Our subsidiary, NuGenerex Diagnostics (NGDx) has b
Post# of 36564
(Total Views: 343)
Posted On: 03/13/2020 2:10:24 PM
Our subsidiary, NuGenerex Diagnostics (NGDx) has been developing and continues to develop rapid, point-of-care diagnostic tests for infectious disease, including syphilis, HIV, tuberculosis-XT, hepatitis B & C, malaria, and dengue virus. These tests have been developed for use by the World Health Organization for distribution in developing countries, particularly Africa.
Based on the foundational kit design developed for field use, NGDx has developed a new, proprietary, patent-pending diagnostic platform, NGDx Express II that will be used for the commercialization of NGDx Express II kit for syphilis, a sexually transmitted disease that has exploded around the world, even in the U.S.A. where infection rates have jumped 76 percent since 2013. The Centers for Disease Control and Prevention, there were nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis reported in the United States in 2017 — the highest cumulative number ever recorded. NGDx is positioned to address this epidemic with rapid, point-of-care diagnostic test kits.
Another area of great need for rapid diagnostic tests is in-hospital infections and sepsis. NGDx is utilizing its proprietary technologies and diagnostic testing experience to develop NGDx Express II for Sepsis and systemic inflammatory response syndrome (SIRS). The long turn-around times for current testing to determine a patient’s infection and status is generally too late; 10% of all patients entering a hospital develop sepsis with a 50% mortality rate. The market for the current underperforming sepsis testing is approximately $3 billion annually.
NGDx is also forming a joint venture for distribution of NGDx Express II test kits for Sepsis/SIRS, HIV, syphilis, and hepatitis B and C in China.
Based on the foundational kit design developed for field use, NGDx has developed a new, proprietary, patent-pending diagnostic platform, NGDx Express II that will be used for the commercialization of NGDx Express II kit for syphilis, a sexually transmitted disease that has exploded around the world, even in the U.S.A. where infection rates have jumped 76 percent since 2013. The Centers for Disease Control and Prevention, there were nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis reported in the United States in 2017 — the highest cumulative number ever recorded. NGDx is positioned to address this epidemic with rapid, point-of-care diagnostic test kits.
Another area of great need for rapid diagnostic tests is in-hospital infections and sepsis. NGDx is utilizing its proprietary technologies and diagnostic testing experience to develop NGDx Express II for Sepsis and systemic inflammatory response syndrome (SIRS). The long turn-around times for current testing to determine a patient’s infection and status is generally too late; 10% of all patients entering a hospital develop sepsis with a 50% mortality rate. The market for the current underperforming sepsis testing is approximately $3 billion annually.
NGDx is also forming a joint venture for distribution of NGDx Express II test kits for Sepsis/SIRS, HIV, syphilis, and hepatitis B and C in China.
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.